RAF Mutation clinical trials at UCSF

1 research study open to eligible people

A raf mutation is a change in a gene that can lead to cancer. UCSF is studying ABM-168 to evaluate its safety and how well it works in adults with advanced solid tumors. This is a Phase 1 trial happening at multiple locations.

Showing trials for

  • ABM-168 in Adults With Advanced Solid Tumors.

    open to eligible people ages 18 years and up

    This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.

    San Francisco, California and other locations

Our lead scientists for RAF Mutation research studies include .

Last updated: